Business Wire

TDK's Subsidiary TDK-Lambda Uses Transphorm GaN to Advance PFH Series AC-DC Power Supply

Share

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and only qualified high-voltage (HV) Gallium Nitride (GaN) semiconductors—today confirmed that leading power supply manufacturer TDK-Lambda, a group company of TDK, has released its first GaN-based AC-DC power supply. The full function 504 W rated PFH500F-28 is the company’s latest generation AC-DC baseplate cooled power supply module. Further, the power module is the latest Transphorm customer product to demonstrate the HV GaN advantages, increasing efficiency by 5 percent in a 28 percent smaller package over the previous PFE500F series.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005041/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TDK-Lambda's PFH500F-28 AC-DC power supply module uses Transphorm's GaN modules for a 30% power density increase. (Graphic: Business Wire)

Broad Industrial Applications Get a Boost

The PFH500F-28 is a low-profile power module with 28 volts of output power designed for various harsh environment applications, commercial off-the-shelf (COTS) power supplies, custom fanless power supplies, traffic signaling, and more. TDK-Lambda’s redesigned standard power module uses a bridgeless totem-pole power factor correction topology to optimize Transphorm’s TPH3206LDG FET in the popular 8x8 PQFN package.

The development project was led by the TDK-Lambda Americas Dallas, TX team and leveraged Transphorm’s application support team throughout various phases of the three-year initiative.

“We are excited to introduce the new standard PFH series,” explained Jin He, Vice President of Engineering at TDK-Lambda. “Our engineers diligently review new technologies that will benefit our end customers to ensure any new product we release is reliable and a notable advancement over prior models. Our decision to work with Transphorm on our first GaN AC-DC product was based largely on the power semiconductors’ proven quality and reliability as well as the team’s reputation for successful collaboration. Our experience was such that we’ve released the PFH500F-28 with our three year warranty and are in discussions with Transphorm regarding future projects.”

Transphorm’s GaN to date has enabled customers to produce computing power supplies, servo motors, and telecom power supplies that show marked advantages in power density, size, and system cost. TDK-Lambda’s power module joins them as the PFH500F-28 delivers the following advantages when compared to its Silicon-based predecessor:

  • Power efficiency: up to 92 percent, a 5 percent increase over the PFE500F
  • Power density: 100W/cubic inch, a 30 percent increase over the PFE500F
  • PMBus™ monitoring and programming (read/write)
  • Size reduction: From 122 x 70 x 12.7 to 101.6 x 61 x 13.5mm, a 28 percent reduction
  • Reduced size of external capacitive components
  • Thermal impact: 38 percent reduction in waste heat, requiring less heatsink/cooling than the PFE500F

About TDK-Lambda Corporation

TDK-Lambda Corporation, a group company of TDK Corporation, is a leading global power supply company providing highly reliable power supplies for industrial equipment worldwide. TDK-Lambda Corporation meets the various needs of customers with our entire range of activities, from research and development through to manufacturing, sales, and service with bases in five key areas, covering Japan, Europe, America, China, and Asia. For more details, please visit https://www.tdk-lambda.com/en/.

Welcome to the GaN Revolution!

Transphorm designs and manufactures the highest performance, highest reliability GaN semiconductors for high-voltage power conversion applications. Holding one of the largest IP portfolios (600+ patents), Transphorm produces the industry’s only JEDEC and AEC-Q101 qualified GaN FETs. This is due to a vertically-integrated business approach, which allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm: moving power electronics beyond Silicon limits. Website: transphormusa.com Twitter: @transphormusa

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Ailara
211 Communications
heather@211comms.com
P: +1.973.567.6040

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye